The Xteink X4 is a tiny eBook reader with a 4.3 inch black and white ePaper display and support for viewing EPUB documents and text files, as well as images. But what really makes this tiny eReader ...
When you tire of social media, you can flip your phone and dive into a good book using this distraction-free e-reader. When you tire of social media, you can flip your phone and dive into a good book ...
The Xteink X4 is a sleek, portable e-reader now available for just $69. While you can use it as a standalone device, it also features a magnetic attachment for compatible smartphones, adding ...
You can always tell when a tech company pays attention to what people want. The Insta360 X4 Air is that rare camera that feels like it was built by listening first, engineering second. After years of ...
On its face, the Insta360 X4 Air doesn't appear to be much of a departure from Insta360's flagship X5 camera, or indeed its older X4 camera. However, there are major changes to be found under the hood ...
Insta360 has launched the X4 Air, a lightweight 8K 360-degree camera with dual 1/1.8-inch sensors starting at $400. It keeps key perks like waterproofing and the Invisible Selfie Stick effect while ...
Insta360 has yet again released a new camera in its 360-degree X family, the Insta360 X4 Air. This is a more affordable, lighter alternative to the Insta360 X5, which was announced in April 2025. It ...
The new Insta360 X4 Air offers 8K 360-degree video recording, advanced stabilization, and waterproof durability in a compact, budget-friendly design. With user-replaceable lenses and a $399 price tag, ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 3 minutes All ...
JAYTON, Texas (KCBD) -Nine months after claming their first title since 1985, the No. 1 Jayton Jaybirds have shown no signs of slowing down. On Thursday, they “45’d” their fourth-straight opponent in ...
X4 Pharmaceuticals is again shrinking its workforce, this time by 50% as the company pushes to save costs and finish a phase 3 study of its Xolremdi (mavorixafor) in neutropenia. The layoffs are ...